DEUTSCHE-POST-DHL-GROUP
Deutsche Post DHL Group (Symbol: DPW), the world’s leading logistics company, has today released preliminary results for the second quarter of 2021. Simultaneously, the outlook for the current financial year and for 2023 has been raised. Furthermore, an one-time corona bonus1 for approximately 550,000 employees worldwide has been decided. Preliminary operating profit (EBIT) for the second quarter has improved to record level with around EUR 2,075 million (Q2 2020: EUR 912 million) and has more than doubled compared to previous year. Against the backdrop of the excellent business performance, the Group has raised its EBIT outlook for 2021 to more than EUR 7.0 billion (so far: more than EUR 6.7 billion). The mid-term EBIT outlook for 2023 is now expected to be more than EUR 7.4 billion (so far: more than EUR 7.0 billion).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005615/en/
“The second quarter proved once again that global trade volume continues to recover and the e-commerce boom is sustainable – and we benefit strongly from both. All divisions continue to operate at full speed worldwide and achieve double-digit EBIT growth rates. We want to thank our employees who do fantastic work around the world and deserve another corona bonus“, said Frank Appel, CEO of Deutsche Post DHL Group.
Group grants once again one-time corona bonus of around EUR 200 million
As an appreciation for their tireless efforts during the pandemic the Group has decided to grant again a corona bonus of EUR 3002 to employees worldwide. This one-time payment is aimed at approximately 550,000 colleagues in all divisions and countries. Excluded are Executives. The corresponding expenses of around EUR 200 million will be booked in the third quarter 2021 and are already included in the updated earnings outlook for 2021.
All divisions achieved a significant jump in earnings
All divisions significantly exceeded the previous year's results. Network capacity utilization was constantly high in the second quarter 2021. B2C shipment volumes remained ahead of last year in all networks, while the recovery in the B2B businesses continued to gain momentum. At the same time the tight capacity situation both in Ocean and Air Freight markets remained unchanged.
Express: EBIT in the Express division reached around EUR 1,170 million in the second quarter 2021 compared to EUR 565 million in the previous year’s quarter.
Global Forwarding, Freight: EBIT in Global Forwarding, Freight stood at around EUR 315 million in the second quarter 2021, also clearly ahead of previous year’s result of EUR 190 million.
Supply Chain: EBIT at Supply Chain came in at around EUR 195 million in the second quarter 2021. It was at EUR 33 million in Q2 2020 in the initial stage of the pandemic.
eCommerce Solutions: eCommerce Solutions recorded EBIT of around EUR 115 million in the second quarter 2021, significantly above last year’s Q2 result which stood at EUR 1 million.
Post & Parcel Germany: EBIT in Post & Parcel Germany in the second quarter 2021 was around EUR 315 million (Q2 2020: EUR 264 million).
The positive business development is underpinned by a continued strong development of cash flow. Free cash flow in the second quarter 2021 amounted to more than EUR 800 million (Q2 2020: EUR 605 million). For the first half of 2021 free cash flow now stands at more than EUR 2.0 billion (H1 2020: EUR 196 million).
Earnings outlook raised in expectation of unchanged high shipment volumes and improved efficiency
In light of the ongoing earnings momentum the Group EBIT for 2021 is now expected to be more than EUR 7.0 billion (so far: more than EUR 6.7 billion). This includes additional expenses of around EUR 200 million for the one-time corona bonus. For the full year 2021, the Group now forecasts a free cash flow of more than EUR 3.2 billion (so far: more than EUR 3.0 billion). Gross capex in 2021 is expected to reach around EUR 3.9 billion (so far: around EUR 3.8 billion). The full year 2021 Group tax rate will now reach 28 percent, the upper end of the previously guided range of 26-28 percent.
Mid-term guidance for Group EBIT 2023 is now expected to be more than EUR 7.4 billion (previously: more than EUR 7.0 billion). The aggregated 2021-2023 guidance for free cash flow was left unchanged at around EUR 9.0 billion. The cumulative outlook for gross capex was also confirmed at around EUR 11.0 billion for the period 2021 to 2023.
The comprehensive disclosure for Q2/H1 2021 will be published as planned on August 5, 2021.
– End –
Deutsche Post DHL Group Deutsche Post DHL Group is the world’s leading logistics company. The Group connects people and markets and is an enabler of global trade. It aspires to be the first choice for customers, employees and investors worldwide. The Group contributes to the world through responsible business practice, corporate citizenship and environmental activities. By the year 2050, Deutsche Post DHL Group aims to achieve zero emissions logistics.
Deutsche Post DHL Group is home to two strong brands: Deutsche Post is Europe’s leading postal service. DHL offers a comprehensive range of international express, freight transport, and supply chain management services as well as e-commerce logistics solutions. Deutsche Post DHL Group employs approximately 570,000 people in over 220 countries and territories worldwide. The Group generated revenues of more than 66 billion Euros in 2020.
THE logistics company for the world.
1
EUR 300 per full-time employee
2
EUR 300 per full-time employee
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005615/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom